摘要
目的探讨诺和锐30联合维格列汀治疗初诊2型糖尿病的临床疗效。方法选取本院2011年10月～2012年10月期间收治的初诊2型糖尿病患者102例，观察组51例，对照组51例，对照组给予诺和锐30治疗，观察组给予诺和锐30联合维格列汀治疗，对两组患者的临床疗效进行比较。结果治疗后，观察组空腹血糖值为（7．21±2．21）mmol／L，餐后血糖值为（9．34±3．01）mmol／L；对照组空腹帆糖值为（10．23±3．02）mmol／L，餐后血糖值为（14．87±3．23）mmol／L。两组患者治疗后空腹血糖值和餐后血糖值差异有统计学意义（P〈0．05）。结论诺和锐30联合维格列汀在初诊2型糖尿病患者的临床治疗方面具有十分确切的疗效，值得临床推广使用。
Objective To explore the clinical efficacy of Novomix 30 combined with Galvus in the treatment of newly diagnosed type 2 diabetes. Methods 102 cases with newly diagnosed type 2 diabetes in our hospital from October 2011 to October 2012 were selected and divided into two groups,the observation group had 51 cases,the control group had 51 cases. The patients in the observation group were treated by Novomix30, the patients in the control group were treated by Novomix30 combined with Galvus,compared and analyzed the clinical efficacy of the two groups. Results After the treatment,in the observation group,the fasting plasma glucose was （7.21 ± 2.21）mmol/L,the postprandial blood glucose value was （9.34 ± 3.01）mmol/L;in the control group,the fasting plasma glucose was（10.23 ± 3.02）mmol/L, the postprandial blood glucose value was （14.87± 3.23）mmol/L. After the treatment,the fasting plasma glucose and postprandial blood glucose value of the two groups had significant difference（P 〈 0.05）. Conclusion Novomix 30 combined with Galvus in the treatment of newly diagnosed type 2 diabetes has precise clinical efficacy,it＇s worthy of promotion.
出处
《中国医药科学》
2013年第6期66-67,共2页
China Medicine And Pharmacy
